CARTITUDE-4: Nearly 75% of patients alive 3 years after cilta-cel treatment for myeloma
Nearly three years after treatment with the chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel (cilta-cel), the risk of death was reduced by 45%
Cellular Therapy
2025 EBMT Annual Meeting
Multiple Myeloma
News
Leukemia
News
Experts issue guidance on treating blood cancers during pregnancy
The incidence of hematologic malignancies presenting during pregnancy has increased, so Georgia Mills, MBBS (Hons), FRACP, FRCPA, of Northern Beaches Hospital in Sydney,
2025 EBMT Annual Meeting
Orca-T immunotherapy reduces GVHD over conventional allogeneic HSCT
Orca-T is an allogeneic stem cell and T-cell immunotherapy that leverages high-purity regulatory T cells to prevent GVHD.
Chronic Lymphocytic Leukemia
News
CHMP recommends pirtobrutinib for relapsed or refractory CLL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of pirtobrutinib for the
Lymphoma
Aggressive B-Cell Lymphomas
Is CAR-T feasible in elderly patients with B-cell lymphoma?
Octogenarians with B-cell lymphoma may be considered for chimeric antigen receptor (CAR) T-cell treatment, according to a study led by Mohamed A. Kharfan-Dabaja,
Lymphoma
Potential risk of lymphoma in individuals with large tattoos
Individuals with tattoos, particularly larger ones, may have an increased risk of lymphoma and skin cancer, according to a recent study. “We are
Leukemia
Lymphoma
Multiple Myeloma
News
Is it time to revisit MRD’s role in relapse detection?
A Viewpoints article published in The Lancet Haematology, calls for further research into the use of measurable residual disease (MRD) in hematologic malignancies.
Myeloproliferative Neoplasms
Polycythemia Vera
News
ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera
The Brazilian Health Regulatory Agency (ANVISA) has approved ropeginterferon alfa-2b (BESREMi) for the treatment of adult patients with polycythemia vera (PV).
Lymphoma
Indolent B-Cell Lymphomas
News
Bexobrutideg earns FDA Orphan Drug status in Waldenström macroglobulinemia
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to bexobrutideg (NX-5948), a first-in-class Bruton’s tyrosine kinase (BTK) degrader, for
Multiple Myeloma
China NMPA approves IND for KPG-818 in relapsed or refractory MM
The Center for Drug Evaluation of the China National Medical Products Administration (NMPA) approved the IND application for KPG-818.